Group items tagged

Switzerland is experiencing medicine shortages due to supply chain issues linked to COVID lockdowns in China and war in Europe, the country's pharmacists association said. "We have the biggest problems with children's medications, especially fever-reducing syrup," Enea Martinelli from pharmaSuisse told Swiss broadcaster SRF. "There are also shortages of blood pressure medications, psychiatric medications and Parkinson's medications," he said.

Teva UK has begun replacing its existing packaging with a new design which is "clearer and easier to read". The new look is "unique, recognisable and distinctive." It "enhances safety and provides a recognisable and distinguishable pack range." One of the UK's leading generics manufacturers, Teva UK supplies more than 500 generic pharmaceutical products to retail and hospital pharmacies. The company says each product within the portfolio is distinguishable by colour, ensuring no two different packs have the same drug and strength colours and with additional product information on the side of the pack and a simplified back, it makes it even easier to identify the correct product when dispensing and supports patients when taking their medication. "Our medicines impact the lives of millions of people every day and our packaging is often the first touchpoint for our patients and our customers", said Kim Innes, general manager of Teva UK and Ireland.

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

The Pharmaceutical Society NI (PSNI)'s Council has decided to freeze the annual registration fee for the current financial year 2023/24. The annual registration fee is considered each year by the PSNI's council. At its meeting in November 2022, Council members in recognition of the effects of the Covid-19 pandemic, the personal and professional impact of the cost of living crisis on pharmacists, and the overall cost of regulation agreed to maintain registration fees at their current level for the next financial year. Pharmaceutical Society NI's Chief Executive Michaela McAleer said: "I am pleased with Council's decision to continue the freeze on registration fees for the 7th successive year. We are acutely aware of the pressures facing the pharmacy profession and hope this can provide some reassurance to the profession as we deal with these financially difficult times.

If you are troubling find the best IVF centre in Delhi? No worries when Crysta IVF is available for you especially when it is recognized as a one-stop solution for all your infertility problems. From working on govt guidelines to following the amalgamation of cutting-edge technologies with modern ART labs, Crysta IVF has been idealized as the best IVF centre in Delhi. Here the doctors have more than two decades of experience in delivering progressive results so that every individual can get the best possible treatment to plan for a healthy baby.

There are a lot of different beauty procedures that you can try in order to achieve healthy-looking skin. It's essential to consult with a dermatologist or other skin care professional to find out which procedures will work best for you, depending on your skin type and concerns. This article will briefly describe some of the different procedures that are available. Here are some contemporary beauty procedures to consider. 1. SKIN NEEDLING Skin needling, also known as micro-needling, is a minimally invasive procedure that can be used to improve the overall appearance of your skin. It involves using a device with fine needles to create tiny punctures on the skin's surface. Additionally, the effects of skin needling can last long after the initial treatment, making it a popular choice for those looking for a more lasting solution. This helps to stimulate collagen production and can reduce the appearance of wrinkles, fine lines, scarring, and other skin imperfections. Skin needling can be done independently or with other treatments such as radiofrequency therapy or chemical peels. It's important to note that skin needling should only be performed by a licensed professional. 2. RADIOFREQUENCY THERAPY If you're unhappy with the way your skin looks, it may be time to consider a radiofrequency therapy treatment. Radiofrequency therapy uses electromagnetic waves to heat up the deeper layers of your skin, stimulating collagen production and improving blood circulation. This can help to improve the appearance of wrinkles, fine lines, and sagging skin. Additionally, radiofrequency therapy can also help to improve the appearance of cellulite and stretch marks. It's a relatively safe and non-invasive procedure, and there is little to no downtime.

Alitam has announced that it has merged with clinical skills training provider MHRx to upskill UK pharmacists so that its chain of community pharmacies in the UK can diagnose and treat minor medical ailments "quickly and safely". This is a second merger deal announced by the group that has 100-plus pharmacies, just days after its merger with Pharmadoctor to "radically transform the UK and Ireland's community pharmacy sector" into a truly preventative healthcare system. Following the merger with MHRx, Alitam will now be providing a career development platform for its pharmacy teams, which also include nurses and other healthcare professionals. MHRx's training incorporates every aspect of general practice alongside relevant topics including making appropriate patient consultation records in line with NHS guidelines. This, Alitam believes, will allow community pharmacies to carry out formal diagnoses, formulate differential diagnosis plans, and perform full clinical examinations. According to the founder and CEO Feisal Nahaboo, mergers such as these will lead to "a healthcare revolution predicated on building the world's first truly preventative healthcare model".

The European Commission is prepared to rewrite European Union law on medicines to ensure stable supply of generic and life-saving medicines in Northern Ireland. In a press statement issued on Friday (Dec 17), the commission said it put forward a package of measures to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland. In the context of the Northern Ireland Protocol, this means that the same medicines will continue to be available at the same time across the United Kingdom. Commenting on the news, policy manager at the National Pharmacy Association (NPA) Helga Mangion said: "We are encouraged by the EU's statement on medicines availability in Northern Ireland, though of course we await the final outcome of the negotiations. We have been talking to the government, the MHRA and other stakeholders about these issues for months, highlighting the concerns of our members in Northern Ireland."

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

The General Pharmaceutical Council (GPhC) has removed a pharmacist from its register who black-marketed 'zolpidem' along with another pharmacist between 2015 and 2016. Dean Zainool Dookhan, a pharmacist first registered with the Royal Pharmaceutical Society of Great Britain on 18 October 2004 and whose registration was later transferred to the General Pharmaceutical Council under registration number 2059808, was jailed last year for exporting 20,000 packets of zolpidem to the Caribbean. While hearing the case on 24-25 May, GPhC's Fitness to Practise Committee stated that "removal of the Registrant's name from the register is the appropriate and proportionate response to his convictions." "The public interest includes protecting the public, maintaining public confidence in the profession, and maintaining proper standards of behaviour. The Committee is entitled to give greater weight to the public interest than the Registrant's own interest in remaining on the register." "The Committee recognises the sanction has a punitive effect in that the Registrant's ability to practise and earn an income as a pharmacist and 28 his professional reputation will be curtailed; it will be five years before he can seek restoration to the register. However, that is the price he must pay for failing to comply with the fundamental tenets of his profession."

An oral drug combination by Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial. In the mid-stage trial, 47 per cent of the patients that were given the two drugs Tafinlar and Mekinist saw their tumours shrink, far above a rate of 11 per cent in a comparative group of participants on standard chemotherapy, the drugmaker said on Monday, June 6. The participants, aged one to 17 years, were suffering from low-grade gliomas (LGG), the most common childhood brain cancer. The trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15 per cent to 20 per cent of paediatric LGG cases. Among further results of the trial with 110 participants, the median time without disease progression was 20.1 months for those given the Novartis drug combo, compared to 7.4 months on chemotherapy. The new oral treatment candidate also caused less severe side effects than burdensome chemotherapy.

Atorvastatin was the most dispensed drug in England in 2021/22 with 53.4 million items, revealed the annual Prescription Cost Analysis (PCA) published by NHS Business Services Authority. According to the official statistics, Apixaban (an anticoagulant) was the drug with the highest cost of £401 million. The statistics revealed that the cost of prescription items dispensed in the community in England was £9.69 billion, a 0.87 per cent increase of £83.7 million from £9.61 billion in 2020/21. "The number of prescription items dispensed in the community in England was 1.14 billion, a 2.58 per cent increase of 28.7 million items from 1.11 billion in 2020/21." FreeStyle Libre 2 Sensor kit (a glucose monitoring system) was the presentation with the largest absolute increase in cost between 2020/21 and 2021/22 of £69.8 million, from £2.84 million to £72.6 million.

Many are well informed about different diseases that involve oral cavities. Fortunately, several medications assist in treating these diseases. Dentists or dental professionals prescribe drugs for dental care, depending on the issue. Specific medications are offered to prevent or treat infection, reduce anxiety, minimize pain and inflammation, treat bacterial infections, teeth cleaning or whitening, and many others. Overall, this article will get you acquainted with some types of medications dental professionals use in caring for their patient's teeth. If you want to know them, then read them on. 1. Conscious Sedation Drugs Many individuals experience anxiety when visiting a dentist. As such, a dentist may apply conscious sedation to ease such feelings. Conscious sedation is part of sedation dentistry in which a dentist alleviates dental anxiety by using sedative medications. The National Institutes of Health stated that you'll still be awake through conscious sedation. However, you'll become more unmindful of the dental procedure. Also, you may forget what occurred afterward. Note that conscious sedation differs from general anesthesia, which assists in making you wholly unconscious, and dentists generally employ this for lengthy dental procedures.

When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug company's factories to boost production of the popular antibiotic. But a few extra shifts was as far as he could go. Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. But, like many other European countries, Spain set the price manufacturers are paid for paediatric amoxicillin when the generic version of the drug was first launched in the country two decades ago, and it has barely budged since. "It's a non-business," said Biosca-Reig, chief executive of Spanish drugmaker Reig Jofre. "We wanted to react, but we had a problem," he said. "The costs go up, the price remains the same."

Community pharmacy workforce is in a fragile condition and faced a shortfall of 3,000 pharmacists in England over a period of five years, a recent research conducted by the Company Chemists' Association (CCA) has revealed. It noted that over the last five years, the net growth of community pharmacists in England a year stood at 733. This is much lower than the required average growth of 1,025, based on data reported by the Health Education England workforce survey from 2021. Acknowledging the discrepancies in the data calculation, the paper published by the association has used "the best available data" to highlight recent changes to the community pharmacy workforce in England. The report noted that despite an increase in the number of pharmacists, many contractors reported an increase in pharmacist vacancies. They also reported a significant increase in locum hourly pay rates, indicating demand exceeds supply.

The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal - have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said. The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I). It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal. The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.

NHS moves a step ahead towards its efforts to address covid-19 backlogs by opening a new 'planned care' hospital in Berkshire dedicated to non-emergency treatment. Heatherwood Hospital in Ascot, part of Frimley Health NHS Foundation Trust, will focus on cutting waits for routine care with staff prioritising patients who have been waiting longest, including for orthopaedic and ophthalmology services. The hospital houses six operating theatres, 48 inpatient beds and 22 day-case cubicles and provides surgical, diagnostic and outpatient care, and will treat patients across Berkshire, Hampshire and Surrey. There will also be a range of outpatient services under the same roof including gynaecology, urology and cardiology services. These will be supported by services offering patients endoscopy, physiotherapy, phlebotomy and radiology checks and treatments.

The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years. Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the completion of the transition to the new Board structure. The Board will meet again on Monday (24 April) to elect the Chair and other appointments. Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits. The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the risk of a loss of organisational memory." "Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required to stand down."

To bring new therapies to market, pharmaceutical, biotechnology, and medical device companies engage contract research organizations (CROs).

The Department of Health of Social Care (DHSC) has re-determined that all six Madopar (Co-beneldopa) preparations meet the special container criteria as outlined in Part II Clause 10 of the Drug Tariff. "The NHS dictionary of medicines and devices (dm+d) has now been updated with special container status applied to the complete pack sizes of all Madopar preparations," said PSNC. "The special container rules apply immediately to all branded or generically written prescriptions for Madopar dispensed from December 2022 onwards." The following products will be treated as special containers for prescriptions dispensed from December 2022 onwards: